Bijoyesh Mookerjee

Bijoyesh Mookerjee

UNVERIFIED PROFILE

Are you Bijoyesh Mookerjee?   Register this Author

Register author
Bijoyesh Mookerjee

Bijoyesh Mookerjee

Publications by authors named "Bijoyesh Mookerjee"

Are you Bijoyesh Mookerjee?   Register this Author

33Publications

3776Reads

37Profile Views

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

J Clin Oncol 2018 01 26;36(1):7-13. Epub 2017 Oct 26.

Vivek Subbiah and Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX; Robert J. Kreitman, National Institutes of Health, Bethesda, MD; Zev A. Wainberg, University of California Los Angeles, Los Angeles, CA; Jae Yong Cho, Yonsei University College of Medicine Gangnam Severance Hospital; Bhumsuk Keam, Seoul National University Hospital, Seoul, Republic of Korea; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht Institute for Pharmaceutical Sciences, Utrecht, the Netherlands; Jean Charles Soria, Institut Gustave Roussy, University of Paris-Sud, and University of Paris-Saclay, Villejuif, France; Patrick Y. Wen, Dana-Farber Cancer Institute, Boston, MA; Christoph Zielinski, Comprehensive Cancer Center, Medical University Vienna; Vienna, Austria; and Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, and Fatima Rangwala, Novartis Oncology, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.6785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791845PMC
January 2018

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.

Pharmacogenomics 2016 Apr 29;17(5):459-62. Epub 2016 Mar 29.

GlaxoSmithKline Research & Development, Stevenage, Hertfordshire, UK.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs.16.4
Publisher Site
http://dx.doi.org/10.2217/pgs.16.4DOI Listing
April 2016

Adenovirus DNA polymerase is recognized by human CD8+ T cells.

J Gen Virol 2009 Jan;90(Pt 1):84-94

Department of Microbiology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1099/vir.0.002493-0DOI Listing
January 2009

Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.

J Immunother 2008 Jan;31(1):81-8

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0b013e318157c668DOI Listing
January 2008

In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy.

J Immunol Methods 2007 Dec 29;328(1-2):169-81. Epub 2007 Sep 29.

Department of Medical Oncology, 1024 Curtis Building, Thomas Jefferson University, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2007.08.013DOI Listing
December 2007

T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.

Biol Blood Marrow Transplant 2007 Dec;13(12):1439-47

The Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2007.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588421PMC
December 2007

Treatment of adenovirus disease in stem cell transplant recipients with cidofovir.

Biol Blood Marrow Transplant 2007 Jan;13(1):74-81

Division of Infectious Diseases and Environment Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2006.08.040DOI Listing
January 2007

Cytoprotection in acute myelogenous leukemia (AML) therapy.

Semin Oncol 2004 Dec;31(6 Suppl 18):67-73

Thomas Jefferson Health System, Blood and Marrow Transplant Program, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2004.12.016DOI Listing
December 2004

Overcoming drug resistance: targeting more than one site.

Leuk Res 2002 Jan;26(1):107-9

Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0145-2126(01)00123-0DOI Listing
January 2002